← Back to headlines
Acadia outlines 2026 revenue target up to $1.28B while advancing DAYBUE STIX and NUPLAZID growth
Acadia Pharmaceuticals has set a 2026 revenue target of up to $1.28 billion, driven by the advancement of DAYBUE STIX and NUPLAZID growth initiatives.
26 Feb, 06:58 — 26 Feb, 06:58
ℹOnly 1 source covers this story
